Steven W Pipe, Cédric Hermans, Meera Chitlur, Manuel Carcao, Giancarlo Castaman, Joanna A Davis, Jonathan Ducore, Amy L Dunn, Miguel Escobar, Janna Journeycake, Osman Khan, Johnny Mahlangu, Shannon L Meeks, Ismail Haroon Mitha, Claude Négrier, Ulrike Nowak-Göttl, Michael Recht, Tammuella Chrisentery-Singleton, Oleksandra Stasyshyn, Kateryna V Vilchevska, Laura Villarreal Martinez, Michael Wang, Jerzy Windyga, Guy Young, W Allan Alexander, Daniel Bonzo, Christopher Macie, Ian S Mitchell, Evelyne Sauty, Thomas A Wilkinson, Amy D Shapiro
INTRODUCTION: Eptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors 12 years of age or older. AIM: To prospectively assess in a phase 3 clinical trial (PERSEPT 2) eptacog beta efficacy and safety for treatment of bleeding in children <12 years of age with haemophilia A or B with inhibitors. METHODS: Using a randomised crossover design, subjects received initial doses of 75 or 225 μg/kg eptacog beta followed by 75 μg/kg dosing at predefined intervals (as determined by clinical response) to treat bleeding episodes (BEs)...
July 2022: Haemophilia: the Official Journal of the World Federation of Hemophilia